Bayer's fine chemicals business unit takes shape
In the two years since the fine chemicals business unit came into being as part of the internal reorganisation of the Bayer group, significant progress has been made, according to Dr Rudolf Hanko, head of the global fine chemicals business unit at Bayer Chemicals.
In the two years since the fine chemicals business unit came into being as part of the internal reorganisation of the Bayer group, significant progress has been made, according to Dr Rudolf Hanko, head of the global fine chemicals business unit at Bayer Chemicals.
The restructuring of the product and technology portfolios and the streamlining of internal processes are now being implemented and are already yielding tangible results in the form of potential annual cost savings of more than Euro 50m, he said.
Approximately 750m3 of non-GMP capacity has been decommissioned, but significant new cGMP capabilities have been added:
•A cGMP Kilolab in ZeTO, was brought online in November and has already produced a new antimalarial API as its first project.
•New cGMP suites at 600l, 2500l, 6000l and 12000l scale in ZeTO were either newly built or substantially improved and are already online.
•Novochem, a flexible cGMP production plant constructed to Bayer specifications by Derivados Quimicos, came on stream in 2002.